The next SysMIC Module 1 course will start on Monday 27th April 2020
SysMIC was developed with BBSRC funding and provides introductory and advanced training in mathematics, statistics and computing for bioscientists. SysMIC is a comprehensive online course in interdisciplinary skills in the life sciences with over 2,000 participants enrolling since its beginning in 2013.
Key topics are:
• Network biology
• Mechanistic modeling, and
• Data analysis
Cambridge, UK, 13th February 2020 / Sciad Newswire / Domainex Ltd is pleased to announce the appointment of Dr Tom Mander as Chief Executive Officer. Dr Mander will take over when Dr Trevor Perrior retires from the role in April 2020. Tom has nearly 30 years of experience in small-molecule drug discovery, and joined Domainex as Chief Operating Officer in March 2015 with a mandate to achieve organic expansion of the drug discovery service business of the company.
Cambridge, UK, 13 February 2020: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for reliable and highly stable droplet generation and processing. Sphere Fluidics will expand operations to meet demand for large-scale commercial supply of its high-performing surfactant for use in a wide range of microfluidic application workflows.
CAMBRIDGE, UK and NEW YORK, USA, 10 February 2020 Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Bryony Harrop as Vice President (VP) of Clinical Development, Bryony will be working alongside Dr Gillian Langford, also VP of Clinical Development, who joined Artios in January 2019.
LOUGHBOROUGH, England (February 3, 2020) – Thermo Fisher Scientific, the world leader in serving science, recently announced the winners of the Fisher Scientific Channel Supplier Awards during its annual Fisher Scientific European Sales Conference held in Madrid.
From January 27-30, 2020, a total of 817 delegates attended the Fisher Scientific European Sales Conference at the Melia Castilla hotel in Madrid. This was the ninth event of its kind, bringing together delegates from 23 different countries.
With the transition period for the new European Medical Device Regulation (EU) 2017/745 (MDR) coming to an end in May 2020, it is imperative that manufacturers take action to update their technical documentation and processes to meet the new requirements.
- Dr Anthony Hall joins at pivotal time, ahead of fragile X syndrome clinical trial initiation.
- Findacure co-founder will apply extensive drug repurposing and rare disease expertise to progress Healx’s drug candidates into the clinic.
Cambridge, UK, 03 February 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth. Dr Catherine Beech joins the PhoreMost Board as a Non-Executive Director. Dr Benedict (Ben) Cross has joined as Senior Director (Technology), and will direct the evolution and development of the Company’s SITESEEKER® screening platform.
As the growing demand for personalised medicines continues, a recent report projects that the global growth of the Advanced Therapy Medical Products (ATMPs) market will also be boosted.
This creates tremendous potential for patients and the industry alike.
Currently there are a small number of licensed products, with many more undergoing clinical trials. In addition to this, there are numerous projects in late phase development about to enter the clinical trial phase.
Cambridge, UK and Milpitas, USA - 30 January 2020 - Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science research and diagnostic markets. ASC is a long-established leader in the edited cell lines market, focused on developing genome editing technologies into novel therapeutics to advance drug discovery.